Mindset Pharma CEO James Lanthier joins Natalie Stoberman from the Proactive studios to discuss the company's latest update to expand into non-hallucinogenic therapeutic drug discovery.
Lanthier says Mindset has been one of the first biotech companies in the psychedelic space to apply state of the art medicinal chemistry and behavioural pharmacology techniques to novel scaffolds of psychedelic drugs with the goal of discovering new medicines. He adds that the company has been working towards discovering novel psychedelic-inspired non-hallucinogenic drug candidates and has found multiple candidates with a promising preclinical profile.